Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $735.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.31, below the -$0.25 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SGMT's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 13 quarters below that had an estimate, SGMT beat 9 and missed 4. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 56.25% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.31 | -$0.25 | -$0.34 - -$0.20 | -24.00% | Miss | N/A | 11 | N/A | Nov 12, 2026 |
| Jun 30, 2026 | -$0.26 | -$0.28 | -$0.33 - -$0.16 | +7.14% | Beat | N/A | 9 | 7 up, 0 down | Aug 11, 2026 |
| Mar 31, 2026 | -$0.33 | -$0.35 | -$0.48 - -$0.21 | +5.71% | Beat | N/A | 8 | N/A | May 12, 2026 |
| Dec 31, 2025 | -$0.29 | -$0.40 | -$0.45 - -$0.23 | +27.79% | Beat | N/A | 8 | 0 up, 0 down | Mar 11, 2026 |
| Sep 30, 2025 | -$0.40 | -$0.39 | -$0.58 - -$0.33 | -2.56% | Miss | N/A | 8 | N/A | Nov 13, 2025 |
| Jun 30, 2025 | -$0.32 | -$0.50 | -$0.64 - -$0.24 | +36.00% | Beat | N/A | 9 | 6 up, 0 down | Aug 13, 2025 |
| Mar 31, 2025 | -$0.56 | -$0.71 | -$1.00 - -$0.54 | +21.13% | Beat | N/A | 6 | 3 up, 0 down | May 8, 2025 |
| Dec 31, 2024 | -$0.50 | -$0.65 | -$0.83 - -$0.37 | +23.08% | Beat | N/A | 6 | 0 up, 0 down | Mar 12, 2025 |
| Sep 30, 2024 | -$0.45 | -$0.40 | -$0.52 - -$0.29 | -12.50% | Miss | N/A | 6 | 0 up, 0 down | Nov 14, 2024 |
| Jun 30, 2024 | -$0.25 | -$0.35 | -$0.40 - -$0.23 | +28.57% | Beat | N/A | 6 | 0 up, 0 down | Aug 14, 2024 |
| Mar 31, 2024 | -$0.23 | -$0.38 | -$0.51 - -$0.32 | +39.47% | Beat | N/A | 6 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.78 | -$0.58 | -$0.71 - -$0.42 | -34.48% | Miss | N/A | 4 | 0 up, 0 down | Mar 25, 2024 |
| Sep 30, 2023 | -$0.35 | -$0.80 | -$1.58 - -$0.45 | +56.25% | Beat | N/A | 4 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$35.80 | -$0.52 | -$0.54 - -$0.44 | N/A | N/A | N/A | 4 | 0 up, 0 down | Jul 14, 2023 |
| Mar 31, 2023 | -$0.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 31, 2023 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.57, after -$1.43 the year before. It was -$37.37 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.57 | N/A |
| Dec 31, 2024 | -$1.43 | N/A |
| Dec 31, 2023 | -$37.37 | N/A |
Frequently Asked Questions About SGMT
Did SGMT beat earnings estimates last quarter?
No. Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.31 for the quarter ended Sep 30, 2026, below the -$0.25 estimate by 24.00%.
What EPS do analysts expect from SGMT next quarter?
The consensus EPS estimate for Sagimet Biosciences Inc. Series A Common Stock for the quarter ending Dec 31, 2026 is -$0.29 from 14 analysts, with estimates from -$0.35 to -$0.22.
How often does SGMT beat earnings estimates?
Sagimet Biosciences Inc. Series A Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +11.79%.
SGMT pages: Overview, Earnings, Forecast, Financials, Competitors